A new study published in the American Journal of Cardiology suggests that some blood pressure medications may be less effective than they should be.
The study is based on a randomized, double-blind, placebo-controlled trial conducted in Japan and Finland that used a combination of drugs to prevent a blood clot from forming in the arteries of volunteers.
The drugs were a combination that contained both calcium channel blocker and a beta blocker, which is more effective at preventing a blood clot.
But the results of the study also suggest that a drug called clorox, which inhibits the activity of the calcium channel, may be as effective as calcium channel blockers as a preventive measure against clotting, according to the authors of the report.
“The data suggest that there may be a gap between what we think is the optimal dose for blood pressure and what actually is a safe amount for people to use,” said Dr. Robert C. Smith, a cardiologist and co-author of the article, which was published on Wednesday in the journal Circulation.
“We’ve known for a while that if you take too much, you’ll probably have a problem.
But it turns out that in fact, there is an upper limit to what is safe.”
The researchers studied the blood pressure of 200 people in the Helsinki and Helsinki-Kokkonen hospitals, which are both in Finland, and compared the patients with blood pressure readings from those who had taken the calcium channels blocker and those who did not.
They also compared the results with results from a small group of volunteers who were not taking any blood pressure drugs.
They found that the blood pressures of the participants taking the calcium blockers and those taking the beta blockers were similar, but the blood tests did not show a difference in the amount of calcium that was released during the clotting process.
“This is really exciting because it gives us a much more precise measurement of what we thought we were getting in the way of a blood pressure lowering effect,” said Smith, who was not involved in the study.
The results of this study suggest that blood pressure pills are not necessarily more effective in preventing clotting than other medications.
“If we can get these drugs into the clinical trial to test them out, we might find that they’re not as effective in reducing the risk of clotting as they’re made out to be,” he said.
The researchers also noted that a recent study found that blood tests are accurate in predicting the level of calcium released during a clotting event, but they do not provide a measure of the level at which calcium is released.
“These results, combined with the fact that they don’t provide a reliable measure of calcium release during a blood test, raises the possibility that there is some discrepancy between what people are actually doing when they take calcium channel blocking drugs and what they think they are doing when their blood pressure drops,” Smith said.
“The data suggests that there are limits to what we would think is safe for people.”
It is important to note that the study only used the calcium blocker.
“A calcium channel inhibitor does not prevent calcium channel inhibition, which would still prevent blood pressure from dropping,” Smith added.
“There is also a difference between what you think you are getting and what is actually happening.”
The calcium channel inhibitors used in the Finnish study, which were administered intravenously, did not lower the level in the blood, so the results did not reflect a difference of blood pressure between the two groups, Smith said, noting that people should also not assume that taking calcium channel blocks will cause blood pressure to drop.
“Caption bias is something that could happen in this study.
Some people think that taking a calcium channel block will make their blood drop, while others believe it will make them have a lower blood pressure,” Smith noted.
“So it’s important that everyone be aware of how they interpret the results, especially when it comes to blood pressure.”
Researchers in Finland are studying the results in more detail and will look for any side effects that could be associated with taking the blood channel blocker, including side effects associated with the drug.
The new results come on the heels of a study in the United States that found that a blood calcium channel control called clomiphene citrate (CCC) reduced the risk for a blood vessel occlusion by nearly 30 percent.
In that study, researchers found that CCC also lowered blood pressure in people with type 2 diabetes, which means that it reduces blood pressure while lowering the risk.
The research was funded by the National Heart, Lung, and Blood Institute and the National Institutes of Health.
More stories from the Middle East and North Africa on The Jerusalem Times.